Clinical trials
Observational Carcinoma, Renal Cell trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
28 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 5 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 17 |
| Unknown status | 5 |
| Recruiting | 4 |
| Terminated | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pfizer | 4 |
| University Hospital, Bordeaux | 4 |
| Assistance Publique - Hôpitaux de Paris | 3 |
| Centre Hospitalier Universitaire de Saint Etienne | 2 |
| Ipsen | 2 |
| Bayer | 1 |
| Bristol-Myers Squibb | 1 |
| Centre Hospitalier Universitaire de Besancon | 1 |
| Centre Hospitalier Universitaire de Nīmes | 1 |
| Centre Hospitalier Universitaire, Amiens | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Renal Cell | 28 |
| Kidney Neoplasms | 9 |
| Carcinoma | 3 |
| Carcinoma, Hepatocellular | 3 |
| Liver Neoplasms | 3 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Colonic Neoplasms | 2 |
| Esophageal Neoplasms | 2 |
| Lung Neoplasms | 2 |
| Neoplasm Metastasis | 2 |
Trials
Showing 1 to 25 of 28. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.